Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc is advancing its clinical pipeline with promising product candidates such as prulacabtagene leucel (prula-cel) and ADI-212, targeting both autoimmune diseases and oncology, with initial data expected for ADI-212 in metastatic castration-resistant prostate cancer in the latter half of 2026. The preliminary Phase 1 data suggesting meaningful efficacy of prula-cel in lupus nephritis (LN) and systemic lupus erythematosus (SLE) enhances its appeal, particularly as the company pursues additional autoimmune indications, which could lead to further upside. Additionally, by contracting third-party manufacturers for commercial-scale production, the company is effectively mitigating manufacturing risks, thereby strengthening its overall investment case.

Bears say

Adicet Bio faces significant financial challenges, projecting a net loss of $11.58 per share for 2026, which raises concerns about the company's economic viability. There are multiple risks compounding these concerns, including negative clinical data, regulatory approvals uncertainty, and potential setbacks in clinical development timelines, all of which could diminish market share and revenue prospects. Additionally, the lack of FDA approval for any Vδ1 gamma-delta T-cell therapies introduces heightened regulatory risks, potentially leading to further investment dilution and lowered expectations for commercial success.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.